-

Bausch + Lomb Announces Second R&D “Teach-in” Webinar

Event will feature detailed overviews of two innovative contact lens technologies with potential to redefine the standard of care

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second event in its R&D “Teach-in” webinar series that provides deeper insights on the company’s robust and differentiated product pipeline.

On Monday, June 1, 2026, at 1:00 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two promising contact lens assets currently under development:

  • First-of-its-kind bioactive contact lens would be the first new contact lens material in over 25 years – designed with polymerized hyaluronic acid to provide all-day comfort, hydration and lubrication
  • Cutting-edge silicone hydrogel daily contact lens featuring premium material and advanced design to help slow the progression of myopia

Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will also participate.

Registration for the live webinar hosted by Citi as part of its Head, Shoulders, Knees, and Toes series can be accessed here. Following the event, a replay will be available on the Investor Relations page of the Bausch + Lomb website.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

© 2026 Bausch + Lomb.

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

More News From Bausch + Lomb Corporation

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company’s broad portfolio of products...

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. “We’re doing exactly what we said we would: driving sustainable growth and margin expansion, improving how we sell and operate and continuing to invest in a pipeline that will carry us forward,” said Brent Saunders, chairman and CEO, Bausch + Lomb. Select Company Highlig...

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmology and Therapy published a narrative review highlighting the role of certain B vitamins in reducing the risk of development and progression of AMD1, a leading cause of vision loss in Americans 50 years of age or older.2 Drawing on more than two decades of scientific research, the publication synt...
Back to Newsroom